Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

74.14
-2.3700-3.10%
Post-market: 74.140.00000.00%19:30 EDT
Volume:480.87K
Turnover:35.82M
Market Cap:2.85B
PE:-11.30
High:76.59
Open:75.89
Low:73.16
Close:76.51
52wk High:99.50
52wk Low:40.00
Shares:38.39M
Float Shares:32.95M
Volume Ratio:1.00
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5619
EPS(LYR):-6.0116
ROE:-39.08%
ROA:-23.96%
PB:4.42
PE(LYR):-12.33

Loading ...

Disc Medicine Price Target Maintained with a $100.00/Share by Wedbush

Dow Jones
·
Yesterday

Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients

TIPRANKS
·
Yesterday

Disc Medicine Highlights Bitopertin Phase 3 EPP Program in Corporate Presentation

Reuters
·
Yesterday

Disc Medicine Says Restore-PV Phase 2 Trial Shows DISC-3405 Cuts Phlebotomy Needs in Polycythemia Vera Patients

Reuters
·
Yesterday

Disc Medicine Presents Initial Results from Restore-Pv Phase 2 Trial in Patients with Polycythemia Vera (Pv) at the 14TH Society of Hematologic Oncology (Soho) Annual Meeting

THOMSON REUTERS
·
Yesterday

Disc Medicine Director Kevin Bitterman Reports Disposal of $135,824.04 in Common Shares

Reuters
·
Yesterday

Disc Medicine Director Kevin Bitterman Disposes of USD 4.36 Million in Common Shares

Reuters
·
Sep 04

Disc Medicine is Maintained at Outperform by Wedbush

Dow Jones
·
Sep 02

Disc Medicine Management Joins Fireside Chats at Upcoming Investor Conferences

Reuters
·
Sep 02

Wedbush Raises Price Target on Disc Medicine to $100 From $88, Keeps Outperform Rating

MT Newswires Live
·
Sep 02

Disc Medicine, Inc. : Wedbush Raises Target Price to $100 from $88

THOMSON REUTERS
·
Sep 02

Disc Medicine to Present Initial Phase 2 Restore-PV Data for DISC-3405 in Polycythemia Vera at SOHO 2026

Reuters
·
Sep 01

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

GlobeNewswire
·
Sep 01

Disc Medicine COO Jonathan Yen-Wen Yu Disposes of 9,096 Common Shares Worth $755,192.83

Reuters
·
Aug 27

Disc Medicine CEO John D. Quisel Disposes of USD 2.63 Million in Common Shares

Reuters
·
Aug 19

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Morgan Stanley Adjusts Price Target on Disc Medicine to $90 From $85, Keeps Overweight Rating

MT Newswires Live
·
Aug 17

Disc Medicine COO Jonathan Yu Reports Sale of 804 Common Shares Worth $66,451.57

Reuters
·
Aug 15

Disc Medicine (IRON) Gets a Buy from Wedbush

TIPRANKS
·
Aug 11

H.C. Wainwright Sticks to Its Buy Rating for Disc Medicine (IRON)

TIPRANKS
·
Aug 10